Recent Updates
Recently added Catalysts
CYTK Negative Sentiment Score: 25/100

CYTOKINETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

Key Takeaway: A class action lawsuit has been filed against Cytokinetics, reminding investors to apply as lead plaintiffs by November 17, 2025. The lawsuit claims that the company and certain executives failed to disclose critical information during the class period, leading to violations of federal securities laws. Notably, the FDA did not convene a meeting regarding the company's NDA for aficamten, which was submitted without a Risk Evaluation and Mitigation Strategy. Due to these disclosures, Cytokinetics' stock price has experienced a noticeable decline.

Market Sentiment Analysis

CONCERNS & RISKS

  • Cytokinetics is facing a class action lawsuit for failing to disclose material information.
  • The FDA declined to hold an advisory committee meeting regarding Cytokinetics' NDA for aficamten.
  • Share prices fell significantly following the news related to the NDA submission.

Full Press Release Details

NEW YORK CITY and NEW ORLEANS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
If you purchased securities of Cytokinetics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-cytk/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 17, 2025.
Cytokinetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 10, 2025, the Company disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for its aficamten product. Then, on May 6, 2025, the Company disclosed that it had held multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy, instead relying on labeling and voluntary education materials.
On this news, the price of Cytokinetics’ shares fell, closing at $33.04 per share on May 7, 2025.
The case is Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file for lead plaintiff in the Cytokinetics lawsuit?

Investors must file lead plaintiff applications by November 17, 2025.

What are the charges against Cytokinetics in this lawsuit?

Cytokinetics and its executives are accused of failing to disclose important information.

When did Cytokinetics announce issues with their New Drug Application?

The announcement about the NDA was made on March 10, 2025.

How can I contact KSF for more information on the lawsuit?

You can reach KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email.

Who is the managing partner of Kahn Swick & Foti, LLC?

The managing partner is Lewis Kahn, a seasoned securities litigation attorney.

Last updated: Oct 1, 2025